OncoMatch/Clinical Trials/NCT04087421
Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome
Is NCT04087421 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Qufora Irrisedo Cone System and Glycerol "OBA" for low anterior resection syndrome.
Treatment: Qufora Irrisedo Cone System · Glycerol "OBA" — The study is a multicentre randomized controlled trial with the objective to compare the effect of transanal irrigation with glycerol suppositories in patients suffering from major Low Anterior Resection Syndrome (LARS).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Prior therapy
Must have received: surgical resection — low anterior resection for rectal cancer
Patients electively treated for rectal cancer with a low anterior resection.
Must have received: treatment for LARS — PCT (presumably pelvic floor/physical therapy or similar) for at least 4 weeks
Unsuccessful PCT after at least 4 weeks of treatment for LARS
Cannot have received: transanal irrigation
Former use of TAI
Cannot have received: systematic use of rectal emptying aids
Prior systematic use of rectal emptying aids
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04087421 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior transanal irrigation, systematic use of rectal emptying aids disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages